tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Aileron Therapeutics (ALRN), NRX Pharmaceuticals (NRXP) and Cybin (CYBN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aileron Therapeutics (ALRNResearch Report), NRX Pharmaceuticals (NRXPResearch Report) and Cybin (CYBNResearch Report) with bullish sentiments.

Aileron Therapeutics (ALRN)

H.C. Wainwright analyst Edward White maintained a Buy rating on Aileron Therapeutics today and set a price target of $1.00. The company’s shares closed last Wednesday at $0.30, close to its 52-week low of $0.26.

According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -27.5% and a 23.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

Aileron Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.00.

See today’s best-performing stocks on TipRanks >>

NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals received a Buy rating and a $2.00 price target from H.C. Wainwright analyst Vernon Bernardino today. The company’s shares closed last Wednesday at $0.57, close to its 52-week low of $0.49.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 21.3% and a 33.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Aridis Pharmaceuticals, and Citius Pharmaceuticals.

Currently, the analyst consensus on NRX Pharmaceuticals is a Moderate Buy with an average price target of $2.00.

Cybin (CYBN)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Cybin today and set a price target of $10.00. The company’s shares closed last Wednesday at $0.56, close to its 52-week low of $0.39.

According to TipRanks.com, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.6% and a 30.6% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Cybin is a Strong Buy with an average price target of $8.35, a 1460.5% upside from current levels. In a report issued on June 23, Canaccord Genuity also maintained a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALRN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles